The effects of atorvastatin and rosuvastatin on oxidative stress in diabetic patients

European Journal of Internal Medicine

Volumn 22, Issue 3, 2011, Pages 249-253

  Koksal, Murat ^a   Eren, Mehmet Ali ^a   Turan, Mehmet Nuri ^a   Sabuncu, Tevfik ^a  

^a HARRAN UNIVERSITY   (Turkey)

Author keywords

Hyperlipidemia; Oxidative stress; Statin; Type 2 diabetes mellitus

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LIPID HYDROPEROXIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETIC PATIENT; DRUG EFFICACY; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PREDICTIVE VALUE; TOTAL ANTIOXIDANT CAPACITY; TOTAL OXIDANT STATUS; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIOXIDANTS; DIABETES MELLITUS, TYPE 2; FEMALE; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PYRIMIDINES; PYRROLES; SULFONAMIDES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79955982098     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2010.12.003     Document Type: Article

References (57)

1. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 2002;23:599-622. (Pubitemid 35191625)
2. Ginsberg HN. Lipoprotein physiology in nondiabetic and diabetic states. Relationship to atherogenesis. Diab Care 1991;14:839-55.
3. Ruan H, Lodish HF. Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-alpha. Cytokine Growth Factor Rev 2003;14(5):447-55. (Pubitemid 37099456)
4. Irshad M, Chaudhuri PS. Oxidant-antioxidant system: role and significance in human body. Indian J Exp Biol 2002;40:1233-9. (Pubitemid 35307153)
5. Schönbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 2004;109(21):18-26.
6. Laufs U, Liao JK. Isoprenoid metabolism and the pleiotropic effects of statins. Curr Atheroscler Rep 2003;5(5):372-8. (Pubitemid 38898896)
7. Davidson M. A Review of the Current Status of the Management of Mixed Dyslipidemia Associated with Diabetes Mellitus and Metabolic Syndrome. Am J Cardiol 2008;102:19-27.
8. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001;21:1712-9. (Pubitemid 34219772)
9. Norata GD, Pirillo A, Catapano AL. Statins and oxidative stress during atherogenesis. J Cardiovasc Risk 2003;10(3):181-9.
10. Bloom HL, Shukrullah I, Veledar E, Gutmann R, London B, Dudley SC. Statins decrease oxidative stress and ICD therapies. Cardiol Res Pract 2010;10:181-9.
11. Davidson M, Ma P, Stein EA, Gotto Jr AM, Raza A, Chitra R, et al. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol 2002;89(3):268-75. (Pubitemid 34113787)
12. Olsson AG, Istad H, Luurila O, Ose L, Stender S, Tuomilehto J, et al. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J 2002;144(6):1044-51. (Pubitemid 36026918)
13. Clearfield MB, Amerena J, Bassand J, Hernández García HR, Miller SS, Sosef FF, et al. Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia-prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR). Trials 2006;7:35.
14. Betteridge DJ, Gibson JM, Sager PT. Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined c-reactive protein (<2 mg/L) and low-density lipoprotein cholesterol (<70 mg/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study). Am J Cardiol 2007;100:1245-8. (Pubitemid 47505225)
15. Singh U, Devaraj S, Jialal I, Siegel D. Comparison effect of atorvastatin (10 versus 80 mg) on biomarkers of inflammation and oxidative stress in subjects with metabolic syndrome. Am J Cardiol 2008;102(3):321-5.
16. Ky B, Burke A, Tsimikas S, Wolfe ML, Tadesse MG, Szapary PO, et al. The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans. J Am Coll Cardiol 2008;51:1653-62. (Pubitemid 351626406)
17. Riad A, Du J, Stiehl S, Westermann D, Mohr Z, Sobirey M, et al. Low-dose treatment with atorvastatin leads to anti-oxidative and anti-inflammatory effects in diabetes mellitus. Eur J Pharmacol 2007;569:204-11. (Pubitemid 47202015)
18. Kurban S, Mehmetoglu I, Ege E. Effect of preoperative atorvastatin therapy on paraoxonase activity and oxidative stress after coronary artery bypass grafting. Perfusion 2009;24(4):271-6.
19. Schupp N, Schmid U, Heidland A, Stopper H. Rosuvastatin protects against oxidative stress and DNA damage in vitro via upregulation of glutathione synthesis. Atherosclerosis 2008;199:278-87.
20. Lu T, Ding Y, Leu H, Yin W, Sheu WH, Chu K. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. Am J Cardiol 2004;94:157-61. (Pubitemid 38902861)
21. Resch U, Tatzber F, Budinsky A, Sinzinger H. Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy. Br J Clin Pharmacol 2006;61(3):262-74. (Pubitemid 43382625)
22. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem 2005;38(12):1103-11.
23. Erel O. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem 2004;37(4):277-85. (Pubitemid 38314881)
24. Arab K, Steghens JP. Plasma lipid hydroperoxides measurement by an automated xylenol orange method. Anal Biochem 2004;325(1):158-63. (Pubitemid 38050279)
25. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease : an update. Hypertension 2001;37:1053-9.
26. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998;316(7134): 823-8. (Pubitemid 28112428)
27. Grundy SM, Cleeman JI, Merz CN, Brewer Jr HB, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004;44(3):720-32.
28. Liao JK. Isoprenoids as mediators of the biological effects of statins. J Clin Invest 2002;110(3):285-8. (Pubitemid 34847957)
29. Berne C. URANUS study investigators. Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study. Cardiovasc Diabetol 2005;3:4-7.
30. Schuster H, Barter PJ, Stender S, Cheung RC, Bonnet J, Morrell JM, et al. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. Am Heart J 2004;147(4):705-13.
31. Kawahito S, Kitahata H, Oshita S. Problems associated with glucose toxicity: role of hyperglycemia-induced oxidative stress. World J Gastroenterol 2009;15(33): 4137-42.
32. Rösen P, Nawroth PP, King G, Möller W, Tritschler HJ, Packer L. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diab Metab Res Rev 2001;17(3):189-212. (Pubitemid 32624602)
33. Prabhakar S, Starnes J, Shi S, Lonis B, Tran R. Diabetic nephropathy is associated with oxidative stress and decreased renal nitric oxide production. J Am Soc Nephrol 2007;18(11):2945-52. (Pubitemid 350058402)
34. Forbes JM, Coughlan MT, Cooper ME. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 2008;57(6):1446-54.
35. Madsen-Bouterse SA, Kowluru RA. Oxidative stress and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Rev Endocr Metab Disord 2008;9(4):315-27.
36. Pan HZ, Zhang H, Chang D, Li H, Sui H. The change of oxidative stress products in diabetes mellitus and diabetic retinopathy. Br J Ophthalmol 2008;92(4):548-51. (Pubitemid 351497989)
37. Vincent AM, Feldman EL. New insights into the mechanisms of diabetic neuropathy. Rev Endocr Metab Disord 2004;5(3):227-36. (Pubitemid 38903580)
38. Cameron NE, Cotter MA, Maxfield EK. Anti-oxidant treatment prevents the development of peripheral nerve dysfunction in streptozotocin-diabetic rats. Diabetologia 1993;36(4):299-304. (Pubitemid 23106012)
39. Ding H, Triggle CR. Endothelial cell dysfunction and the vascular complications associated with type 2 diabetes: assessing the health of the endothelium. Vasc Health Risk Manage 2005;1(1):55-71.
40. Stephens JW, Gable DR, Hurel SJ, Miller GJ, Cooper JA, Humphries SE. Increased plasma markers of oxidative stress are associated with coronary heart disease in males with diabetes mellitus and with 10-year risk in a prospective sample of males. Clin Chem 2006;52(3):446-52.
41. Meerwaldt R, Links T, Zeebregts C, Tio R, Hillebrands JL, Smit A. The clinical relevance of assessing advanced glycation endproducts accumulation in diabetes. Cardiovasc Diabetol 2008;7:29.
42. Son SM. Role of vascular reactive oxygen species in development of vascular abnormalities in diabetes. Diab Res Clin Pract 2007;77:65-70.
43. Ceriello A, Bortolotti N, Pirisi M, Crescentini A, Tonutti L, Motz E, et al. Total plasma antioxidant capacity predicts thrombosis-prone status in NIDDM patients. Diab Care 1997;20(10):1589-93. (Pubitemid 27415039)
44. Maxwell SR, Thomason H, Sandler D, Leguen C, Baxter MA, Thorpe GH, et al. Antioxidant status in patients with uncomplicated insulin-dependent and noninsulin-dependent diabetes mellitus. Eur J Clin Invest 1997;27(6):484-90. (Pubitemid 27288358)
45. Bolayirli IM, Aslan M, Balci H, Altug T, Hacibekiroglu M, Seven A. Effects of atorvastatin therapy on hypercholesterolemic rabbits with respect to oxidative stress, nitric oxide pathway and homocysteine. Life Sci 2007;81(2):121-7. (Pubitemid 46921173)
46. Wenzel P, Daiber A, Oelze M, Brandt M, Closs E, Xu J, et al. Mechanisms underlying recoupling of eNOS by HMG-CoA reductase inhibition in a rat model of streptozotocin-induced diabetes mellitus. Atherosclerosis 2008;198(1):65-76.
47. Save V, Patil N, Moulik N, Rajadhyaksha G. Effect of atorvastatin on type 2 diabetic dyslipidemia. J Cardiovasc Pharmacol Ther 2006;11(4):262-70. (Pubitemid 44936240)
48. Ajith TA, Riji T, Anu V. In vitro anti-oxidant and DNA protective effects of the novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin. Clin Exp Pharmacol Physiol 2008;35(5-6):625-9.
49. Otto A, Fontaine D, Fontaine J, Berkenboom G. Rosuvastatin treatment protects against nitrate-induced oxidative stress. J Cardiovasc Pharmacol 2005;46(2):177-84. (Pubitemid 41060210)
50. Gómez-García A, Martínez Torres G, Ortega-Pierres LE, Rodríguez-Ayala E, Alvarez-Aguilar C. Rosuvastatin and metformin decrease inflammation and oxidative stress in patients with hypertension and dyslipidemia. Rev Esp Cardiol 2007;60(12):1242-9. (Pubitemid 350294323)
51. Qu HY, Xiao YW, Jiang GH, Wang ZY, Zhang Y, Zhang M. Effect of atorvastatin versus rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in patients with hypercholesterolemia. Pharm Res 2009;26(4):958-64.
52. Calkin AC, Giunti S, Sheehy KJ, Chew C, Boolell V, Rajaram YS, et al. The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation. Diabetologia 2008;51(9):1731-40.
53. Fuhrman B, Koren L, Volkova N, Keidar S, Hayek T, Aviram M. Atorvastatin therapy in hypercholesterolemic patients suppresses cellular uptake of oxidized-LDL by differentiating monocytes. Atherosclerosis 2002;164(1):179-85. (Pubitemid 34765651)
54. Nagila A, Permpongpaiboon T, Tantrarongroj S, Porapakkham P, Chinwattana K, Deakin S, et al. Effect of atorvastatin on paraoxonase1 (PON1) and oxidative status. Pharmacol Rep 2009;61(5):892-8.
55. Orem C, Orem A, Uydu HA, Celik S, Erdöl C, Kural BV. The effects of lipid-lowering therapy on low-density lipoprotein auto-antibodies: relationship with lowdensity lipoprotein oxidation and plasma total antioxidant status. Coron Artery Dis 2002;13(1):65-71. (Pubitemid 34274252)
56. Sodha NR, Boodhwani M, Ramlawi B, Clements RT, Mieno S, Feng J, et al. Atorvastatin increases myocardial indices of oxidative stress in a porcine model of hypercholesterolemia and chronic ischemia. J Card Surg 2008;23(4):312-20. (Pubitemid 351852564)
57. Dobreanu M, Gǎlǎţeanu C, Simionescu A, Deac R. Effects of atorvastatin on some inflammatory parameters in severe primary hypercholesterolemia. Rom J Intern Med 2002;40(1-4):61-73.